Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
6.16
-0.08 (-1.28%)
At close: Aug 1, 2025, 4:00 PM
6.22
+0.06 (0.97%)
After-hours: Aug 1, 2025, 7:58 PM EDT

Company Description

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.

It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.

Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Tenax Therapeutics, Inc.
Tenax Therapeutics logo
CountryUnited States
Founded1967
IndustryBiotechnology
SectorHealthcare
Employees6
CEOChristopher Giordano

Contact Details

Address:
101 Glen Lennox Drive, Suite 300
Chapel Hill, North Carolina 27517
United States
Phone919 855 2100
Websitetenaxthera.com

Stock Details

Ticker SymbolTENX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000034956
CUSIP Number88032L209
ISIN NumberUS88032L6056
Employer ID26-2593535
SIC Code2834

Key Executives

NamePosition
Christopher T. GiordanoChief Executive Officer, President and Director
Dr. Stuart Rich M.D.Chief Medical Officer and Director
Thomas A. McGauleyPrincipal Financial Officer and Principal Accounting Officer
Doug RandallChief Business Officer
Dr. Douglas Hay Ph.D.Executive Vice President of Regulatory Affairs

Latest SEC Filings

DateTypeTitle
Jun 30, 2025SCHEDULE 13GFiling
Jun 17, 20258-KCurrent Report
May 15, 2025SCHEDULE 13G/AFiling
May 15, 2025SCHEDULE 13GFiling
May 14, 202510-QQuarterly Report
May 14, 20258-KCurrent Report
May 14, 2025SCHEDULE 13G/AFiling
Apr 25, 2025ARSFiling
Apr 25, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025DEF 14AOther definitive proxy statements